Ironwood Pharmaceuticals, Inc. - Class A IRWD
Analyst Ratings
- Consensus
- Moderate Buy — 1 Buy · 1 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $7.50 (+76.5% upside)
Key Stats
- Today's Range
- $4.01 – $4.26
- 50-Day Range
- $3.55 – $4.88
- 52-Week Range
- $0.71 – $5.78
- Volume
- 1.67 million shs
- Average Volume
- 1.97 million shs
- Market Cap
- $682.44 million
- P/E Ratio
- 5.52
- Dividend Yield
- —
Valuation
- P/E Ratio
- 5.52
- Price / Book
- -4.22
- Price / Sales
- 1.75
Short Interest
- Short Interest
- 11.02%
- Days to Cover
- 22.23
Financials (TTM)
- Revenue
- $389.32 million
- Net Income
- $129.87 million
- Net Margin
- 33.36%
- Return on Equity
- -80.24%
- Debt-to-Equity
- —
About Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Related Stocks
Compare head-to-head: IRWD vs LLY·IRWD vs JNJ·IRWD vs ABBV·IRWD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.